Taking the Helm at Helus: A Brief Q&A With New CEO Michael Cola
This morning, Helus Pharma announced the appointment of Michael Cola as CEO. Here, Psychedelic Alpha’s Josh Hardman speaks with the newly appointed executive in a brief Q&A on execution, regulatory rigour, and scaling serotonergic CNS medicines.
Josh Hardman, Psychedelic Alpha: How does your background in specialty pharma support Helus?
Michael Cola, Helus: I have spent my career taking differentiated medicines from late-stage development through approval and into real-world use, which is often where CNS programs struggle most...
Join Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
- Regular Bulletins featuring news, analysis, and research
- Articles and deep dives across psychedelic drug development, policy, and research
- Exclusive interviews with researchers, executives, and policymakers
- Bespoke resources and tools including the Psychedelic Bill Tracker
- Quarterly video briefings and slide decks
Already a member?
Sign In